Axovant Sciences to Present at Upcoming Investor Conferences
BASEL, Switzerland, Jan. 25, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced upcoming presentations at two investor conferences:
- February 16 at 1:30 p.m. EST at the Leerink Partners 6th Annual Global Healthcare Conference
- February 22 at 11:30 a.m. EST at the RBC Capital Markets 2017 Healthcare Conference
A simultaneous webcast will be available for each conference in the Investors section of Axovant's website at www.axovant.com. A replay will be available for 30 days following each conference.
About Axovant SciencesAxovant Sciences is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of this condition.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-upcoming-investor-conferences-300396884.html
SOURCE Axovant Sciences
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Axon wins federal contracts for cameras, drones, and Tasers
- Moomoo Advances Investor Education for a Third Year with Nasdaq, Integrating Advanced Market Data and AI-Powered Assistants into Its Global Paper Trading Competition
- California Opens New Workforce Pell Grant Application Portal for Institutions to Determine Career Training Program Eligibility
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share